Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | SGN-B6A + SGN-PDL1V |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| SGN-B6A | SGN B6A|SGNB6A|anti-integrin beta-6/MMAE ADC SGN-B6A|Sigvotatug vedotin | SGN-B6A is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting integrin beta-6 linked to monomethyl auristatin E, which delivers the anti-microtubule agent to integrin beta-6-expressing tumor cells, potentially resulting in inhibition of tumor growth (PMID: 37619980). | ||
| SGN-PDL1V | SGNPDL1V|SGN PDL1V|PF-08046054|PF08046054|PF 08046054 | PD-L1/PD-1 antibody 138 | SGN-PDL1V is an antibody-drug conjugate (ADC) comprised of a monoclonal antibody targeting CD274 (PD-L1) linked to monomethyl auristatin E (MMAE), which potentially induces cytotoxicity, immune activation, and inhibition of tumor growth (J of Clin Oncol 40, no. 16_suppl (June 01, 2022) TPS3154). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07227298 | Phase Ib/II | SGN-B6A + SSGJ-707 SGN-B6A + SGN-PDL1V | Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers | Recruiting | USA | ITA | FRA | ESP | DEU | 4 |